octapharma
For the treatment of VWD

February 2, 2015

 

Octapharma USA Launches Co-Pay Assistance

Program for Patients Receiving wilate®

 

Eligible Patients Can Receive Financial Support for Co-Payments,

Co-Insurance and Deductibles Without Regard for Ability to Pay

 

HOBOKEN, N.J. (February 2, 2015) – Octapharma USA today announced a new financial support program for the bleeding disorders community. The Octapharma Co-Pay Assistance Program is available to von Willebrand’s Disease (VWD) patients who are currently receiving wilate®  [von Willebrand Factor/Coagulation Factor VIII Complex (Human)]or have a prescription to begin therapy.

 

The new program offers eligible patients a maximum of $6,000 annually for co-pay, co-insurance and deductible expenses associated with their treatment without regard for their ability to pay. Patients must have third-party commercial insurance to participate in the program.

 

“We realize that patient out-of-pocket expenses associated with healthcare can sometimes be daunting, therefore, Octapharma has committed to support a program specifically designed to supplement these costs,” said Octapharma USAPresident Flemming Nielsen. “Octapharma is focused on creating support programs that adapt to meet patient needs and ensure continued access to therapies recommended by their medical providers. Coupled with ongoing educational programs, these efforts emphasize our strong belief that patient needs must always come first.”

 

To enroll in the Octapharma Co-Pay Assistance Program, eligible patients should contact the Octapharma Support Center at (800) 554-4440.The program is not available to patients who are covered under Medicaid, Medicare, MediGap, VA, DOD, TRICARE or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program. Participants must be residents of the United States.

 

Important Risk Information

wilate® is a plasma-derived, highly purified concentrate of freeze-dried human von Willebrand factor (VWF) and coagulation factor VIII (FVIII). Two well-established virus inactivation steps are incorporated into the manufacturing process of wilate®, specifically a solvent/detergent (S/D) and terminal dry-heat (TDH) treatment.

 

wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand Disease (VWD), as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

 

wilate® is contraindicated for patients who have known anaphylactic or severe systemic reaction to plasma-derived products, any ingredient in the formulation, or components of the container. Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement therapies. FVIII activity should be monitored to avoid sustained excessive FVIII levels. wilate® is made from human plasma. The risk of  infectious agents, including viruses and, theoretically, the Creutzfeldt-Jacob disease agent, cannot be completely eliminated. The most common adverse reactions to treatment with wilate® in patients with VWD have been uticaria and dizziness. The most serious adverse reactions to treatment with wilate® have been hypersensitivity reactions.

 

For more information and full prescribing information on wilate®, please visit www.wilateusa.com.

 

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation since 1983. Its core business is the development and production of human proteins from human plasma and human cell-lines. Octapharma employs approximately 6,000 people worldwide to support the treatment of patients in over 100 countries with products across the following therapeutic areas:  Hematology (coagulation disorders), Immunotherapy (immune disorders) and Critical Care. The company’s American subsidiary, Octapharma USA, is located in Hoboken, N.J. Octapharma operates two state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com, www.octagamus.net, www.octaplasus.com or www.wilateusa.com.

 

MEDIA CONTACT:

Fred Feiner

Yankee Public Relations

fred@yankeepr.com

908-425-4878

###

OCTA-043-PPR

 

Octapharma USA, Inc.• 121 River Street, Suite 1201• Hoboken, NJ 07030 • 201-604-1130 • www.octapharmausa.com

 

Photos are of models and for illustrative purposes only.

NEWS

MEDIA CONTACT:

Fred Feiner
Yankee Public Relations
(908) 425-4878
fred@yankeepr.com

Copyright © 2017. Octapharma USA Inc. All Rights Reserved.